… that affects normal function — is increased in PD brains compared to controls. This modification reduces neuroprotection by … cerebrospinal fluid of patients with PD. Final Outcome The goal of our project is to test whether 14-3-3 … Access to Data and Biospecimens …

… Michael J. Fox Foundation for Parkinson’s Research (MJFF) today announced the initiation of its first target … yielded 21 priority targets and their pathways, which now guide MJFF’s near-term validation efforts and form the … of the program’s next phase. With the selection process complete, T2T is now shifting from target identification to …

… these pre-clinical models for translational studies and early clinical trials. Impact on Diagnosis/Treatment of Parkinson’s Disease:  If our USP30 … parallel safety testing, we will progress our inhibitor into human trials, confirming that enough USP30 inhibitor …

… was one of the first in line to turn to technology as a means of monitoring her health. Each morning she puts on her … was really easy to find trials that needed volunteers like me.” Laurine has participated in several studies leveraging … like me to be heard in PD research, even if we don’t live near a research center.” Emerging technologies are changing …

… these symptoms inn patients. MJFF currently is looking into when these sorts of symptoms begin in Parkinson’s patients, but some research indicates that these cognitive changes can occur early in disease progression. “Sanofi approached us about …

… in the brain, which scientists believe may contribute to disease progression. MJFF supported Inflazome researchers for laboratory development of therapies against NLRP3 , a protein that … treatments through expensive clinical testing,” said MJFF Vice President of Research Programs Marco Baptista, PhD. “The …